Skip to main content

Table 4 Longitudinal assessments in follow-up early PD patients

From: Parkinson's disease peripheral immune biomarker profile: a multicentre, cross-sectional and longitudinal study

Characteristics Baseline (n = 39) Follow-up (n = 39) p value
Age (years) 68.5 ± 7.7 / /
Sex, N    /
 Male 26 / /
 Female 13 / /
Disease duration (years)    
 UPDRS I 3.3 ± 2.7 6.3 ± 4.1  < 0.001***
 UPDRS II 9.9 ± 4.3 12.1 ± 4.8 0.041
 UPDRS III 18.8 ± 8.5 26.9 ± 9.6  < 0.001***
 NMSQ 8.2 ± 4.1 10.6 ± 4.3 0.014
 SS-16 6.7 ± 3.3 5.6 ± 2.5 0.099
 RBDSQ 5.0 ± 4.3 5.7 ± 3.6 0.45
 HAMD-17 5.7 ± 4.4 6.1 ± 4.7 0.71
 SCOPA-AUT 13.8 ± 9.6 16.1 ± 8.5 0.27
 MMSE 27.2 ± 3.5 27.5 ± 2.8 0.60
 MoCA 23.2 ± 5.2 22.8 ± 5.4 0.76
  1. Data are expressed as mean and standard deviation (SD), as appropriate
  2. The bold emphasis in the table means p < 0.05
  3. NMSQ the Non-Motor Symptom Questionnaire, SCOPA-AUT Scale for Outcomes in PD-Autonomic, SS-16 Sniffin’ Sticks 16-item test, HAMD-17 17-item Hamilton Depression Rating Scale, MMSE Mini-Mental State Examination, MoCA Montreal Cognitive Assessment, iRBD idiopathic REM sleep behavior disorder